Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: First-in-human dose-escalation study

with No hi ha comentaris
  • Gazzah, A., Bedard, P. L., Hierro, C., Kang, Y. -., Abdul Razak, A., Ryu, M. -., . . . Tabernero, J. (2022). Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: First-in-human dose-escalation study. Annals of Oncology. https://doi.org/10.1016/j.annonc.2021.12.012 (En premsa)

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *